ImmunoCellular Therapeutics Expands Cancer Immunotherapy Platform with Antigen-Specific T-cell Technology Licensed from Caltech
Caltech's technology addresses the challenge, and limitation, that CAR (chimeric antigen receptor) and TCR (T-cell receptor) technologies have faced of generating a limited, short-lived immune response. By putting T-cell receptors into stem cells rather than into T-cells, the immune response can be transformed into a long-lived and potent response that could effectively treat previously resilient solid cancers. This observation has been verified in animal models by investigators at Caltech and the
"The Baltimore et al. novel approach to generating antigen-specific T-cells for cancer therapy has potential advantages over other T-cell therapeutic approaches. Our goal is to generate a first clinical candidate from this new discovery platform, and expand our existing dendritic cell expertise into the adjacent fields of stem cells and T-cells," said
Financial terms of the licensing agreement are not being disclosed.
Caltech is a world-renowned research and education institution focused on science and engineering, where faculty and students pursue new knowledge about our world and search for the kinds of bold and innovative advances that will transform our future. The scientific, engineering, and technological contributions of Caltech's faculty and alumni have earned national and international recognition, including 33 Nobel Prizes. Caltech's 300 professorial faculty members offer a rigorous science and engineering curriculum to approximately 1,000 undergraduates and 1,300 graduate students, providing one of the nation's lowest student-to-faculty ratios. The Institute also manages the
Forward-Looking Statements for
This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including the risk that the technology licensed from Caltech can be successfully developed or result in product candidates, and whether ICT-107 can be further successfully and timely developed or commercialized. Additional risks and uncertainties are described in IMUC's most recently filed quarterly report on Form 10-Q and annual report on Form 10-K. Except as permitted by law, IMUC undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
News Provided by Acquire Media